T2-Low Asthma Gets a Roadmap for Diagnosis and Targeted Treatment
A major review clarifies how to identify and manage T2-low asthma, a poorly understood subtype lacking standard biomarkers and biologics.
Summary
T2-low asthma — defined by the absence of eosinophilic inflammation — affects a significant portion of asthma patients yet remains difficult to diagnose and treat. This 2025 review outlines the key phenotypes (obesity-related, aging-related, neutrophilic, paucigranulocytic), explains why standard biomarkers fall short, and evaluates emerging therapies. Azithromycin stands out, showing potential to induce clinical remission in up to 50% of uncontrolled T2-low patients by targeting microbial dysbiosis. Anti-TSLP therapy and bronchial thermoplasty offer additional options. Looking ahead, IL-33 pathway biologics and GLP-1/GIP receptor agonists for obesity-related cases represent promising avenues requiring further investigation.
Detailed Summary
Asthma is not a single disease, and the T2-low subtype — defined by the absence of Type 2 eosinophilic airway inflammation — presents unique diagnostic and therapeutic challenges. Unlike T2-high asthma, where biologics targeting IL-4, IL-5, and IL-13 pathways have transformed care, T2-low patients have few proven add-on options and are frequently under-recognized due to missing specific biomarkers and the confounding effect of corticosteroids suppressing existing markers.
This comprehensive 2025 review by Thomas and colleagues synthesizes current evidence on T2-low asthma's prevalence, phenotypes, and management. The authors note that T2-low asthma appears more common in mild-to-moderate disease than in severe asthma, with distinct phenotypic clusters including late-onset, aging-related, obesity-related, neutrophilic, and paucigranulocytic subtypes. Importantly, many patients with severe T2-low asthma may shift to a T2-high inflammatory pattern during exacerbations, complicating phenotypic classification.
The most clinically significant finding highlighted is azithromycin's potential to induce remission in up to 50% of uncontrolled T2-low asthma patients. Its mechanism appears linked to correcting microbial dysbiosis in the airway, opening a novel therapeutic angle. Anti-thymic stromal lymphopoietin (anti-TSLP) therapy and bronchial thermoplasty are also discussed as viable adjuncts for selected patients.
Looking to the future, the authors flag GLP-1 and GIP receptor agonists — the same drug class behind semaglutide — as particularly relevant for obesity-related T2-low asthma, given obesity's mechanistic role in this phenotype. IL-33 pathway biologics are also in view.
A key caveat is that much of the evidence base for T2-low treatment remains limited in size and specificity. Biomarker thresholds vary across studies, and long-term outcomes for severe T2-low asthma are poorly characterized, underscoring the need for dedicated clinical trials in this population.
Key Findings
- Azithromycin may induce clinical remission in up to 50% of uncontrolled T2-low asthma patients via microbial dysbiosis correction.
- T2-low asthma appears more prevalent in mild-to-moderate asthma than in severe disease.
- Severe T2-low asthma may transiently shift to a T2-high inflammatory pattern during exacerbations.
- GLP-1/GIP receptor agonists are emerging candidates for obesity-related T2-low asthma management.
- No specific biomarkers exist for T2-low asthma; corticosteroids further suppress existing markers, complicating diagnosis.
Methodology
This is a narrative review article published in the Journal of Allergy and Clinical Immunology: Practice, synthesizing published literature on T2-low asthma diagnosis and treatment. As a review, it does not report original trial data but evaluates and integrates existing evidence across studies with varying designs and biomarker cutoffs.
Study Limitations
The review is based solely on existing literature without new primary data, and many cited studies have small sample sizes or heterogeneous biomarker definitions. Long-term outcomes for severe T2-low asthma remain poorly characterized, limiting prognostic guidance. Corticosteroid-induced biomarker suppression continues to hinder accurate prevalence estimation and phenotype classification.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: